MDxHealth (MDXH) EBITDA (2021 - 2026)

MDxHealth (MDXH) has 6 years of EBITDA data on file, last reported at -$4.3 million in Q1 2026.

• Quarterly EBITDA fell 226.0% year-over-year to -$4.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$4.1 million (up 63.9% YoY) and the FY2025 annual result came in at -$1.1 million, up 92.29% from the prior year.
• EBITDA declined to -$4.3 million in Q1 2026 per MDXH's latest filing, from -$2.1 million in the prior quarter.
• The five-year high for EBITDA was $17.5 billion in Q3 2022, with the low at -$17.5 billion in Q2 2022.
• Average EBITDA over 5 years is -$5.4 million, with a median of -$4.4 million recorded in 2023.
• Year-over-year, EBITDA soared 127.82% in 2025 and slumped 226.0% in 2026.
• MDxHealth's EBITDA stood at -$8.9 million in 2022, then soared by 51.15% to -$4.4 million in 2023, then jumped by 68.47% to -$1.4 million in 2024, then plunged by 53.27% to -$2.1 million in 2025, then plunged by 105.45% to -$4.3 million in 2026.
• Business Quant data shows MDXH's EBITDA at -$4.3 million in Q1 2026, -$2.1 million in Q4 2025, and $952000.0 in Q3 2025.